Dupilumab Decreases Local Galectin‐10 Expression in Eosinophilic Chronic Rhinosinusitis
- 15 May 2025
- journal article
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (8) , 876-880
Abstract
No abstract availableKeywords
Funding Information
- Japan Agency for Medical Research and Development (JP22ek0410097)
- Ministry of Health, Labour and Welfare ((202213003A))
This publication has 8 references indexed in Scilit:
- Dupilumab‐induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitisAllergy, 2023
- Increased Circulating Cell-Free DNA in Eosinophilic Granulomatosis With Polyangiitis: Implications for Eosinophil Extracellular Traps and ImmunothrombosisFrontiers in Immunology, 2022
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trialsThe Lancet, 2019
- Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic RhinosinusitisThe Journal of Allergy and Clinical Immunology: In Practice, 2019
- Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC StudyAllergy, 2015
- Eosinophil Granule Proteins: Form and FunctionJournal of Biological Chemistry, 2014
- Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humansBlood, 2013
- Targeting eosinophils in allergy, inflammation and beyondNature Reviews Drug Discovery, 2013